ArticleOncoTargets and therapy2018

Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.

Marco D DiBonaventura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.